• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer

    2016-03-24 10:46:02ZhengYangLuYuZheWang
    Chinese Journal of Cancer Research 2016年1期

    Zheng Yang*, Lu Yu*, Zhe Wang

    1State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Xi’an 710032, China;2The First Cadet Brigade, Fourth Military Medical University, Xi’an 710032, China

    *These authors contributed equally to this work.

    Correspondence to: Prof. Zhe Wang. State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Fourth Military Medical University, Xi’an 710032, China. Email: zhwang@fmmu.edu.cn.

    ?

    PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer

    Zheng Yang1,2*, Lu Yu1*, Zhe Wang1

    1State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Xi’an 710032, China;2The First Cadet Brigade, Fourth Military Medical University, Xi’an 710032, China

    *These authors contributed equally to this work.

    Correspondence to: Prof. Zhe Wang. State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Fourth Military Medical University, Xi’an 710032, China. Email: zhwang@fmmu.edu.cn.

    Abstract:The incidence of prostate cancer (PCa) is rising steadily among males in many countries. Serum prostate-specific antigen (PSA) is widely applied to clinical diagnosis and screening of PCa. However, the so-called grey area of PSA levels 4.0–10.0 ng/mL has a low specificity of 25–40% resulting in a high rate of negative biopsy and overtreatment. So in order to treat PCa patients in early stage, there is an urgent need for new biomarkers in PCa diagnosis. The PCA3 gene, a non-coding RNA (ncRNA) that is highly expressed in prostate cancer (PCa) cells, has been identified as a molecular biomarkers to detect PCa, of which PCA3 has already under clinical application. PCA3 is strongly overexpressed in malignant prostate tissue compared to benign or normal adjacent one. Newly, PCA3 is considered to be a promising biomarker in clinical diagnosis and targeted therapy. The diagnostic signifi cance of PCA3, however, is awaiting further researches. Moreover, it has been demonstrated recently that TMPRSS2-ERG gene fusion is identifi ed as the predominant genetic change in patients diagnosed with PCa. Recent study revealed that combination of the PCA3 and TMPRSS2-ERG gene fusion test optimizes PCa detection compared with that of single biomarker, which would lead to a considerable reduction of the number of prostate biopsies. In this review, we focused on the potential use of PCA3 and TMPRSS2-ERG gene fusion detection in the diagnosis of PCa.

    Keywords:Prostate; prostate cancer antigen 3 (PCA3); TMPRSS2-ERG gene fusion; prostate cancer (PCa); biomarker

    Submitted Apr 26, 2015. Accepted for publication Jan 19, 2016.

    View this article at: http://dx.doi.org/10.3978/j.issn.1000-9604.2016.01.05

    Introduction

    Prostate cancer (PCa) has become as a leading causes of cancer death in many countries among males (1). In recent year, the incidence of PCa have showed an obvious growth trend in China. PCa is becoming urinary tract malignant tumor that impacts Chinese men’s health seriously.

    As a n invasive testing method, the histopathologic evaluation of prostate biopsies is served as the golden standard for the diagnosis of PCa. At the early stage, PCa does not present with patent clinical manifestation. The decision of prostate biopsies implement relies largely on serum prostate-specific antigen (PSA) testing and digital rectal examination (DRE) (2). The limitations of PSA as PCa early detection biomarker are sound discussed, and the controversy of its use in the screening setting were highlighted recently (3). The so-called grey area of PSA levels 4.0–10.0 ng/mL has a low specificity of 25–40% resulting in a high rate of negative biopsy (4). In addition, DRE is very subjective leading to numerous false positive results and many unnecessary biopsies. Thus, there is an urgent need for new biomarkers in the diagnosis of PCa.

    With significant advances in genetics and cell biology, numerous PCa biomarkers have been found recently. Increasing evidence has shown that long non-coding RNAs, such as pro state cancer antigen 3 (PCA3) might be servedas promising biomarkers in the diagnosis of PCa. PCA3 was initially known as DD3, located on chromosome 9q21-22. The PCA3 gene, widely studied in recent years, is probably one of the first biomarkers which already under clinical application. Highly overexpression of PCA3 in PCa tissue was found to be a potential non-invasively prediction of prostate biopsy which might be a promising biomarker in clinical diagnosis (5). The Clinical has focused mainly on an assay about transcription-mediated amplification (TMA, Progensa PCA3 test). Authoritatively, the assay has been approved by the US Food and Drug Administration (FDA) and is Community European (CE) marked for assessing the risk of PCa in men who has a previous negative biopsy (6).

    One of the earliest genetic variation, ERG oncogene, identifi ed as a transcription factor of ETS family, located on chromosomal band 21q22 is overexpressed in over 50% of PCa (7). Transmembrane protease, serine 2 (TMP RSS2), a prostate-specific and androgen regulated gene, locates very closer to ERG on the same chromosome. It has been identified that the overexpression of ERG in major PCa was driven by fusing with TMPRSS2 (8). In recent studies, TMP RSS2-ERG gene fusion is the pervasive variant in about 40% to 70% PCa (9). Due to various detecting method, it is expected that TMPRSS2-ERG gene fusion might be a promising biomarker of PCa.

    Probably, urine and venous blood specimens after prostate massage is the most easily obtained specimen for biomarkers detection. It could be collected non-invasively and is available in large amount. Urine markers are especially attractive when the prostate in the early stage disease and setting of screening (10). We have searched the literatures by using the key words PCA3, TMPRSS2, ERG, and PCa, and reviewed all the published papers. We focus on the potential value of the PCA3 and TMPRSS2-ERG gene fusion, especially for their ability to calculate patient risk with ever negative biopsy for the occult cancer.

    PCA3: molecular science and clinical use

    PCA3, named as differential display clone 3 (DD3) initially, found by Bus semakers et al. in 1999, was specifically expressed in PCa tissue from 10- to 100-fold in relation to non-neoplastic prostatic surrounding tissue in 53 of 56 patients treated with radical prostatectomy (11). PCA3 is a non-coding RNA located on chromosome 9q21-22, contains a high density of stop codons, whose biological function is not well-known. Recent study suggested that PCA3 modulated the transcriptional activity of androgen receptor target genes which might play a role in the control of PCa cell survival (12).

    Since PCA3 was discovered by Bussemakers et al., various methods of the measurement has developed, such as Progensa TM PCA3 test, which promote the clinical applicability of PCA3 in the diagnosis of PCA. To evaluate the potential usefulness of PCA3 as a diagnostic marker for PCa, a time-resolved fluoresce-based quantitative RT-PCR assay has been developed. Urine specimens were collected after prostate massage. It has been reported that compared with normal prostate tissue, PCA3 overexpression is 66-fold up-regulated in PCa tissue (13). It also suggested that an average 11-fold up-regulation in prostate tissue specimens containing fewer than 10% PCa cells (13), which means that polymerase chain reaction assay can detected a few cancer cells in a background of normal cells, prompted the potential assay of PCA3 in urine.

    In the study accompanying this review, Merola et al. report on PCA3 in PCa and tumor aggressiveness detection on 407 high-risk patients (3). The PCA3 test showed the best diagnostic function when compared with tPSA and f/tPSA, promoting the choice of high-risk patients that may benefit from the operation of a traumatic prostatic biopsy. In addition, the PCA3 test could show a prognostic value, which higher PCA3 score values would relate to greater tumor aggressiveness.

    PCA3 guides the decision making of prostate biopsy

    The golden standard for the diagnosis of PCa is the histopathologic evaluation of prostate biopsy, which is an invasive testing method. The decision of implementing prostate biopsy relies on PSA testing and DRE. Although raised levels of serum PSA are suggestive of PCa, yet, diagnostic confirmation requires a transrectal prostatic needle biopsy, which is an invasive procedure. Still there is the so-called grey area of PSA levels 4.0–10.0 ng/mL has a low specificity of 25–40% resulting in a high rate of negative biopsy (4). Among those previous negative prostate biopsy, 10–35% can be indentified cancer by a systematic repeat prostate biopsy, which result in a high proportion of unnecessary biopsies (14,15). While making a decision of initial or repeat prostate biopsy, the risk of unnecessary biopsy which leads to complication and patient discomfort, pain, anxiety, waste cost have to be taken into consideration. The PCA3 score is the ratio of PCA3 mRNA to PSA mRNA multiplied by 1,000. Many large-scale multicenterclinical studies have confirmed that the PCA3 score can overcome the disadvantages of the low specificity of the traditional PSA test. Recent data suggested that PCA score is correlated with the positive rate of prostate biopsy (16). It showed that when a PCA3 cutoff score of 35 was used during the fi rst prostate biopsy, the sensitivity and specifi city increased to 82.3% and 89.0% respectively. Compared to using PSA, the best PSA cutoff value of sensitivity and specificity showed only 57.4% and 53.8%, the priority of PCA score is obvious (17-20). An European study suggested that the area under the curve (AUC) of PCA3 was 0.761 and 0.65 in initial and repeat prostate biopsy respectively (16). The synthesis of these finding demonstrated that using PCA3 score at guiding both initial and repeat biopsy has priority over PSA testing.

    Some research suggested that PCA3 has a higher diagnostic accuracy, but strength of evidence was insuf fi cient to conclude that PCA3 testing leads to improve health outcome (21).

    PCA3 and Gleason score

    Histologic differentiation of PCa is closely related to the prognosis, biologic behavior, treatments option and patient outcome. Gleason grading system is used to evaluate the prognosis of PCa based on its microscopic appearance (22). The present results indicated a correlation between PCA3 and Gleason score (23). However, some data suggested that there was no diff erence between the migrated Gleason score tumor group and the group of confirmed Gleason score tumors, thus the ability of PCA3 to predict final Gleason score was limited. In addition, a PCA3 score >35 di d not appear in a multivariate analysis as an independent factor of a Gleason score >7. Consequently, it is blurred of the clinical impact of PCA3 and Gleason score correlation is ambiguous (24).

    Although there are some limitations of PCA3 application, it is still considered as a useful clinical tool in the diagnosis of PCa, especially when the viewpoint of combining PCA3 assay with other markers has been raised up, such as TMPRSS2-ERG gene fusion, another biomarker of PCa (25).

    TMPRSS2-ERG gene fusion in PCa

    ERG gene was identified as a transcription factor of ETS family (26,27), which involved in chromosome translocations in Ewing family of tumors as well as in leukemias. In 2005, frequent overexpression of ERG in PCa was observed (28). Later that year, it was discovered that the mechanism underlying this overexpression was the recurrent genomic rearrangement between the fi rst exon(s) of TMPRSS2 and the ERG oncogenes (29). It had been confirmed that The fu sion of TMPRSS2 and ERG genes appeared in nearly 50% of PCa patients (30,31). TMPRSS2 is an androgen-regulated gene that is preferentially expressed in the prostate (32). TMPRSS2 is located on chromosomal band 21q22. ERG maps also 21q22 in the same orientation, at a distance of approximately 3 Mb. The fusion of the androgen- and prostate-specific regulating sequences and first exon(s) of TMPRSS2 to the coding sequences of ERG resulted in the androgen-regulated overexpression of ERG.

    TMPRS S2-ERG gene fusion in the activation oftra nsforming growth factor beta/smads signaling pathway

    Although the specific role of TMPRSS2-ERG fusion in PCa is not well understood, yet ERG-positive patients have a low rate of high Gleason grade, poor diff erentiation compared to ERG-negative patients (33,34). TMPRSS2-ERG gene fusions may be cancer-initiating, and expressed at both RNA and protein levels in PCa stem cells (34,35). It also has been shown that an anti-epileptic drug targets ERG-positive PCa cells through the activation of tumor suppressors and nuclear receptors (36).

    Recent studies found that it might play an important role in the acitivation of Transforming Growth Factor Beta/Smads Signaling Pathway (37). It is well known that TGF-β signaling pathway involved in cell proliferation, differentiation, migration, adhesion, apoptosis, embryonic development, and is even related to human diseases including cardiovascular, fibrosis, reproductive, wounded healing disorders and cancer (38,39). After TGF-β ligand binding to its receptor, R-Smads (receptor-regulated Smads) including Smad2 and Smad3 protein are phosphorylated, and then form a complex by interacted with Smad4. The complex then translocate into nucleus and bind to target genes.

    It is common to find genetic alteration and recurrent gene fusion between ERG and TMPRSS2 on chromosome 21 in prostate. In these PCa cases, ERG gene expression is significantly upregulated by the androgen-responsive promoter of TMPRSS2. Although the role of TMPRSS2-ERG gene fusion protein in PCa is not well understood, recentresults found that over-expression of ERG may be a useful biomarker of PCa diagnosis.

    TMPRSS2-ERG gene fusion in small cell carcinoma (SCC) of PCa

    SCC, accounts for less than 2.0% of de novo PCa, is a rare variant neuroendocrine tumor of the prostate (40). Compared with prostatic adenocarcinoma, which accounts for most PCas, prostatic SCC shows obvious difference in clinicopathologic features. Most prostati c adenocarcinomas hardly have clinical manifestation and can be identifi ed by an increase of PSA. The process of prostatic adenocarcinomas is slow and the metastasis often occurs at advanced stage. Responding well to androgen ablation treatment, patients with prostati c adenocarcinomas can achieve long life expectancy (41).

    On the contrary, patients with prostati c SCC show no increase in PSA. And the disease progresses rapidly with metastasis at very early stage. For the lack of androgen receptor, prostatic SCC shows resistance to androgen ablation (42). SCC can originate in various organs, such as lung, cervix, prostate, urinary bladder, etc., with the lung being the most common origin. As SCCs arising from diff erent organs share similar histologic, immunohistochemical, and ultrastructural features (43-45), it may be difficult to deduce the origin when SCC is observed in the prostate especially after its metastasis. Besides it, most prostatic SCCs lose the prostate-specific immunohistochemical markers, such as prostatic acid phosphatase, PSA, prostate-specific membrane antigen, and protein (44). Therefor e, a specific molecular marker to distinguish the prostatic origin of SCC may be clinically useful.

    Despite the frequent occurrence of ERG gene rearrangements in adenocarcinoma, the incidence of these rearrangements in prostatic SCC is unclear. Recent study found that the presence of ERG rearrangements in nearly half of the prostatic SCCs is a similar rate of rearrangement that found in prostatic acinar carcinomas. Furthermore, the high concordance rate of ERG rearrangement between the SCC and adenocarcinoma components in a given patient supports a common origin for these two subtypes of PCa. The absence of TMPRSS2-ERG gene fusion in bladder or lung SCCs highlighted the utility of detecting TMPRSS2-ERG gene fusion in SCCs of unknown primary for establishing prostatic origin and identified a promising molecular marker for establishing prostatic origin in SCCs of unknown primary (46).

    Evaluation of PCA3 and TMPRSS2- ERG gene fusions as diagnostic biomarkers for PCa

    The gold standard for the diagnosis of (PCa) is based on the histopathologic evaluation of prostate biopsies, an invasive procedure associated with patients’ discomfort, anxiety and severe complications. Because localized PCa often does not present with symptoms, the selection of men qualifying for prostate biopsies relies on serum PSA testing and digital r ectal examination (DRE). However, PSA has a low specifi city resulting in a high negative biopsy rate (47). And DRE is very subjective. A specific biomarker of PCA is required for clinical diagnosis.

    In 2006, the TMPRSS2-ERG gene fusion transcripts were successfully detected in urine samples (48). This urine test had a sensitivity of 37% and a specificity of 93% for the prediction of PCa on prostate biopsy (7). TMPRSS2-ERG had great predictive value to PCA3 and the European Randomised study of Screening for Prostate Cancer (ERSPC) risk calculator parameters for predicting PCa (6).

    Recent st udy shown that both PCA3 and TMPRSS2-ERG fusion had independent additional predictive value for predicting PCa. Recent study suggested that applying this biomarker panel of PCA3 combine with TMPRSS2-ERG fusion to clinical diagnosis could avoid 35% negative prostate biopsies, missing only 10% of the men with PCa with a Gleason score-7 (7). Implementing the novel biomarker panel PCA3 and TMPRSS2-ERG into clinical practice would lead to a considerable reduction of prostate biopsies.

    However, some cohort studies and meta-analysis revealed that TMPRSS2-ERG fusion status was not a strong predictor of PCa recurrence or cancer-specific mortality. The role of TMPRSS2-ERG in PCa pathogenesis and progression is only starting to emerge (49). Recent study proposed prostate health index (PHI) calculated by a mathematical formula combining PSA molecular forms, which also can off er a reduction in unnecessary biopsy (50).

    Conclusions

    Formerly, PCa candidates biopsy selection relies largely on serum PSA testing and digital rectal examination (DRE). However, due to the lack of specificity, new biomarkers of PCa is needed urgently. Unfortunately, PCA3 test also has limitations. For instance, patients with indolent tumors present a low PCA3 score which PCA3 test cannot exclude.

    Since TMPRSS2-ERG gene fusions has been detectedin a significant portion of PCa, it is identified as a potential diagnostic and therapeutic target of PCa, especially in SCC. And recent study showed a great ascendance of biomarker panel combining PCA3 and TMPRSS2-ERG in PCa diagnosis, which may prevail in clinical practice. Therefore, in order to optimize the PCa detection, combining the PCA3 and TMPRSS2-ERG gene fusion test might have applicable diagnostic.

    Acknowledgements

    Funding: This work was supported by the following grants: National Natural Science Foundation of China No. 31571413, 31201037 (to Dr. Yu) and No. 81570180, 81072103 (to Dr. Wang) from the National Natural Science Foundation of China.

    Footnote

    Confl icts of Interest: The authors have no confl icts of interest to declare.

    References

    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.

    2. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-37.

    3. Merola R, Tomao L, Antenucci A, et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 highrisk patients: a National Cancer Institute experience. J Exp Clin Cancer Res 2015;34:15.

    4. Roddam AW, Duff y MJ, Hamdy FC, et al. Use of prostate-specifi c antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99; discussion 398-9.

    5. Jung M, Xu C, Spethmann J, et al. Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16. Eur Urol 2004;46:271-2.

    6. Tomlins SA. Urine PCA3 and TMPRSS2:ERG using cancer-specifi c markers to detect cancer. Eur Urol 2014;65:543-5.

    7. Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8.

    8. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009;56:275-86.

    9. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-8.

    10. Locke JA, Black PC. Next generation biomarkers in prostate cancer. Front Biosci (Landmark Ed) 2016;21:328-42.

    11. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specifi c gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.

    12. Ferreira LB, Palumbo A, de Mello KD, et al. PCA3 noncoding RNA is involved in the control of prostatecancer cell survival and modulates androgen receptor signaling. BMC Cancer 2012;12:507.

    13. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15; discussion 15-6.

    14. Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000;163:1144-8; discussion 1148-9.

    15. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167:2435-9.

    16. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92.

    17. Ochiai A, Okihara K, Kamoi K, et al. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int 2013;111:928-33.

    18. Salagierski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort. Anticancer Res 2013;33:553-7.

    19. Pepe P, Aragona F. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-fi nding protocol. Can J Urol 2013;20:6620-4.

    20. Goode RR, Marshall SJ, Duff M, et al. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate 2013;73:48-53.

    21. Bradley LA, Palomaki GE, Gutman S, et al. Comparative eff ectiveness review: prostate cancer antigen 3 testing forthe diagnosis and management of prostate cancer. J Urol 2013;190:389-98.

    22. Epstein JI, Pound CR, Partin AW, et al. Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol 1998;160:97-100; discussion 101.

    23. Miller K. Words of wisdom. Re: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. Whitman EJ, Groskopf J, Ali A, et al. J Urol 2008;180:1975-8; discussion 1978-9. Eur Urol 2009;56:218-9.

    24. Durand X, Xylinas E, Radulescu C, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 2012;110:43-9.

    25. Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65:534-42.

    26. Rao VN, Papas TS, Reddy ES. erg, a human etsrelated gene on chromosome 21: alternative splicing, polyadenylation, and translation. Science 1987;237:635-9. 27. Reddy ES, Rao VN, Papas TS. The erg gene: a human gene related to the ets oncogene. Proc Natl Acad Sci U S A 1987;84:6131-5.

    28. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-52.

    29. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions defi ne a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-400.

    30. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008;21:67-75.

    31. Shah RB, Chinnaiyan AM. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. Adv Anat Pathol 2009;16:145-53.

    32. Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specifi c TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009;15:6398-403.

    33. Hu Y, Dobi A, Sreenath T, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008;14:4719-25.

    34. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 2008;105:2105-10.

    35. Polson ES, Lewis JL, Celik H, et al. Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. Nat Commun 2013;4:1623.

    36. Fortson WS, Kayarthodi S, Fujimura Y, et al. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and aff ect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol 2011;39:111-9.

    37. Fang J, Xu H, Yang C, et al. Molecular Mechanism of Activation of Transforming Growth Factor Beta/Smads Signaling Pathway in Ets Related Gene-Positive Prostate Cancers. J Pharm Sci Pharmacol 2014;1:82-85.

    38. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000;92:1388-402.

    39. Tian M, Neil JR, Schiemann WP. Transforming growth factor-β and the hallmarks of cancer. Cell Signal 2011;23:951-62.

    40. Palmgren JS, Karavadia SS, Wakefi eld MR. Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 2007;34:22-9.

    41. Wang HT, Yao YH, Li BG, et al. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol 2014;32:3383-90.

    42. Stein ME, Bernstein Z, Abacioglu U, et al. Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications--a retrospective study of 30 patients from the rare cancer network. Am J Med Sci 2008;336:478-88.

    43. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002;26:1184-97.

    44. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:65-71.

    45. Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006;30:705-12.

    46. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011;24:820-8.

    47. Stephan C, Schnorr D, Loening SA, et al. Re: RoddamAW, Duff y MJ, Hamdy FC, et al. Use of prostate-specifi c antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99. Eur Urol 2005;48:1059-60; author reply 1060-1.

    48. Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8:885-8.

    49. Pettersson A, Graff RE, Bauer SR, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21:1497-509.

    50. Bruzzese D, Mazzarella C, Ferro M, et al. Prostate health index vs percent free prostate-specifi c antigen for prostate cancer detection in men with "gray" prostate-specifi c antigen levels at fi rst biopsy: systematic review and metaanalysis. Transl Res 2014;164:444-51.

    Cite this article as: Yang Z, Yu L, Wang Z. PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chin J Cancer Res 2016;28(1):65-71. doi: 10.3978/j.issn.1000-9604.2016.01.05

    doi:10.3978/j.issn.1000-9604.2016.01.05

    女人高潮潮喷娇喘18禁视频| 老司机午夜十八禁免费视频| 一级a爱视频在线免费观看| 国产高清有码在线观看视频 | 久久久国产精品麻豆| 亚洲 欧美一区二区三区| 久久久水蜜桃国产精品网| 中文字幕久久专区| 天堂动漫精品| 日韩大尺度精品在线看网址| 亚洲av成人av| 精品第一国产精品| 88av欧美| 成人欧美大片| 欧美日韩中文字幕国产精品一区二区三区| 久久 成人 亚洲| 久久久久久大精品| 搡老熟女国产l中国老女人| 日韩欧美免费精品| 国产免费男女视频| 国产伦人伦偷精品视频| 不卡av一区二区三区| 日本免费a在线| 岛国在线观看网站| 色精品久久人妻99蜜桃| 中文亚洲av片在线观看爽| 国产色视频综合| 丝袜在线中文字幕| 亚洲人成伊人成综合网2020| 人人妻人人澡人人看| 香蕉国产在线看| 叶爱在线成人免费视频播放| 久久婷婷人人爽人人干人人爱| 免费在线观看影片大全网站| netflix在线观看网站| 国产精品久久久久久人妻精品电影| 亚洲人成网站在线播放欧美日韩| 国产av又大| 婷婷精品国产亚洲av在线| 黄色女人牲交| 亚洲九九香蕉| 丝袜人妻中文字幕| 国内精品久久久久久久电影| 色尼玛亚洲综合影院| 久久久久久国产a免费观看| 成人永久免费在线观看视频| 两个人视频免费观看高清| 欧美成人午夜精品| 三级毛片av免费| 在线观看免费日韩欧美大片| 亚洲一卡2卡3卡4卡5卡精品中文| 欧美性猛交╳xxx乱大交人| 亚洲激情在线av| av天堂在线播放| 久久国产精品影院| 久久狼人影院| www.精华液| 视频区欧美日本亚洲| 成年版毛片免费区| 欧美色视频一区免费| 国产野战对白在线观看| 国产精品永久免费网站| 91成年电影在线观看| 欧美精品亚洲一区二区| 欧美日韩福利视频一区二区| 18禁黄网站禁片免费观看直播| 亚洲天堂国产精品一区在线| 久久久国产精品麻豆| 国语自产精品视频在线第100页| 别揉我奶头~嗯~啊~动态视频| 日韩成人在线观看一区二区三区| 国产又黄又爽又无遮挡在线| a级毛片a级免费在线| 少妇 在线观看| 黄色片一级片一级黄色片| 久久国产精品男人的天堂亚洲| 黄色a级毛片大全视频| 国产黄色小视频在线观看| 亚洲精品国产区一区二| 少妇的丰满在线观看| 亚洲男人天堂网一区| 国产伦在线观看视频一区| 亚洲五月婷婷丁香| 久久人人精品亚洲av| 午夜久久久久精精品| 国产精品自产拍在线观看55亚洲| 777久久人妻少妇嫩草av网站| 国产极品粉嫩免费观看在线| 日韩欧美一区视频在线观看| 黄色毛片三级朝国网站| 亚洲精华国产精华精| 日本五十路高清| 50天的宝宝边吃奶边哭怎么回事| 日本a在线网址| 老熟妇仑乱视频hdxx| 国产久久久一区二区三区| a级毛片a级免费在线| 成人特级黄色片久久久久久久| 欧美黄色淫秽网站| 国产精品二区激情视频| 岛国在线观看网站| 国内精品久久久久久久电影| 亚洲第一青青草原| 亚洲va日本ⅴa欧美va伊人久久| 午夜精品久久久久久毛片777| 国产主播在线观看一区二区| 真人做人爱边吃奶动态| 一边摸一边抽搐一进一小说| 精品久久久久久,| 国产精品野战在线观看| 色精品久久人妻99蜜桃| 午夜福利18| 成人欧美大片| 午夜福利视频1000在线观看| 巨乳人妻的诱惑在线观看| 人人妻人人看人人澡| 欧美乱妇无乱码| 他把我摸到了高潮在线观看| 欧美性长视频在线观看| 三级毛片av免费| 天堂√8在线中文| 国产亚洲av高清不卡| 精品欧美一区二区三区在线| 国产亚洲欧美在线一区二区| 在线观看www视频免费| 法律面前人人平等表现在哪些方面| 免费高清在线观看日韩| 免费在线观看影片大全网站| 日韩欧美国产在线观看| 欧美zozozo另类| 午夜福利欧美成人| 精品国产国语对白av| 在线观看日韩欧美| 99精品欧美一区二区三区四区| av免费在线观看网站| 人妻久久中文字幕网| 免费观看人在逋| 国产真实乱freesex| 国产欧美日韩一区二区精品| 日韩高清综合在线| 欧美在线一区亚洲| 日本免费a在线| a级毛片a级免费在线| 国产男靠女视频免费网站| 99久久99久久久精品蜜桃| 日本撒尿小便嘘嘘汇集6| 嫩草影院精品99| 女人高潮潮喷娇喘18禁视频| 亚洲国产欧美网| 亚洲人成伊人成综合网2020| 亚洲av电影在线进入| 亚洲 国产 在线| 窝窝影院91人妻| 亚洲精品国产一区二区精华液| 日韩一卡2卡3卡4卡2021年| 国产成人av教育| 日本撒尿小便嘘嘘汇集6| 国产伦人伦偷精品视频| 中文字幕人成人乱码亚洲影| 天天一区二区日本电影三级| 亚洲欧美精品综合久久99| 亚洲av第一区精品v没综合| www日本黄色视频网| 亚洲av五月六月丁香网| 大型av网站在线播放| 少妇粗大呻吟视频| √禁漫天堂资源中文www| 国产精品 国内视频| 久久婷婷人人爽人人干人人爱| 变态另类成人亚洲欧美熟女| 国内久久婷婷六月综合欲色啪| 久久精品成人免费网站| 国产一卡二卡三卡精品| 欧美三级亚洲精品| 精品国内亚洲2022精品成人| 日本一区二区免费在线视频| 日韩视频一区二区在线观看| 久久国产乱子伦精品免费另类| 天天一区二区日本电影三级| 99热这里只有精品一区 | 搡老妇女老女人老熟妇| 国产又爽黄色视频| 亚洲av五月六月丁香网| 午夜久久久久精精品| 亚洲色图 男人天堂 中文字幕| 老汉色av国产亚洲站长工具| 精品电影一区二区在线| 亚洲av成人一区二区三| 可以免费在线观看a视频的电影网站| 亚洲av第一区精品v没综合| 两个人免费观看高清视频| 久久久久国产精品人妻aⅴ院| 日本在线视频免费播放| 欧美乱妇无乱码| 亚洲无线在线观看| 97人妻精品一区二区三区麻豆 | 久久久久久免费高清国产稀缺| 国产99久久九九免费精品| 午夜老司机福利片| 狠狠狠狠99中文字幕| 久久中文看片网| 日韩精品青青久久久久久| 中文字幕精品免费在线观看视频| 午夜久久久在线观看| 国产亚洲av嫩草精品影院| 国产午夜精品久久久久久| 亚洲精品一区av在线观看| 国产黄片美女视频| 又大又爽又粗| 精品国产美女av久久久久小说| 悠悠久久av| 一本大道久久a久久精品| www.熟女人妻精品国产| 欧美日韩一级在线毛片| 中文字幕另类日韩欧美亚洲嫩草| avwww免费| 99久久久亚洲精品蜜臀av| 亚洲专区字幕在线| 国内久久婷婷六月综合欲色啪| 欧美色视频一区免费| 日韩欧美免费精品| 91麻豆精品激情在线观看国产| 男人舔女人的私密视频| 欧美激情久久久久久爽电影| 九色国产91popny在线| 日本撒尿小便嘘嘘汇集6| 1024视频免费在线观看| 欧美性猛交黑人性爽| avwww免费| 男人舔女人的私密视频| 美女国产高潮福利片在线看| 50天的宝宝边吃奶边哭怎么回事| 成年免费大片在线观看| a在线观看视频网站| 丝袜美腿诱惑在线| 婷婷六月久久综合丁香| 一进一出抽搐gif免费好疼| 久久精品亚洲精品国产色婷小说| 欧美大码av| 在线av久久热| 日韩大码丰满熟妇| 丝袜美腿诱惑在线| 欧美黑人欧美精品刺激| 国产成人系列免费观看| 身体一侧抽搐| 婷婷亚洲欧美| 韩国精品一区二区三区| 国产蜜桃级精品一区二区三区| 99re在线观看精品视频| 亚洲美女黄片视频| 亚洲美女黄片视频| 在线免费观看的www视频| 欧美日韩亚洲综合一区二区三区_| 99热只有精品国产| 午夜a级毛片| 村上凉子中文字幕在线| 老熟妇仑乱视频hdxx| 午夜两性在线视频| 天天一区二区日本电影三级| 黄色毛片三级朝国网站| 亚洲天堂国产精品一区在线| 精品久久蜜臀av无| 精品无人区乱码1区二区| 亚洲成av人片免费观看| a级毛片在线看网站| 桃红色精品国产亚洲av| 国产激情偷乱视频一区二区| 成人三级黄色视频| 亚洲精品久久国产高清桃花| 免费一级毛片在线播放高清视频| 村上凉子中文字幕在线| 国产精品 国内视频| 看免费av毛片| 午夜福利18| 国产精品av久久久久免费| 国产久久久一区二区三区| 久久久久久免费高清国产稀缺| 日韩视频一区二区在线观看| 亚洲avbb在线观看| 侵犯人妻中文字幕一二三四区| 亚洲精品色激情综合| 欧美日韩福利视频一区二区| 亚洲va日本ⅴa欧美va伊人久久| 一进一出好大好爽视频| 国产精华一区二区三区| 九色国产91popny在线| 亚洲成人久久性| 亚洲精品国产精品久久久不卡| 午夜精品在线福利| 在线国产一区二区在线| 国产又色又爽无遮挡免费看| 日本 欧美在线| 免费观看精品视频网站| av天堂在线播放| 啪啪无遮挡十八禁网站| 熟女少妇亚洲综合色aaa.| 精品不卡国产一区二区三区| or卡值多少钱| 欧洲精品卡2卡3卡4卡5卡区| 国产精品综合久久久久久久免费| 免费观看人在逋| 美女扒开内裤让男人捅视频| 国产成人欧美| 国内毛片毛片毛片毛片毛片| 欧美中文综合在线视频| 久久久久久免费高清国产稀缺| 亚洲av电影在线进入| 夜夜夜夜夜久久久久| 国产激情偷乱视频一区二区| 婷婷精品国产亚洲av在线| 叶爱在线成人免费视频播放| www.熟女人妻精品国产| 国产视频一区二区在线看| 亚洲精品美女久久av网站| 日本撒尿小便嘘嘘汇集6| 日本熟妇午夜| 香蕉av资源在线| 99热6这里只有精品| 老司机在亚洲福利影院| 久久久水蜜桃国产精品网| 久热爱精品视频在线9| 香蕉丝袜av| netflix在线观看网站| av有码第一页| 中文字幕高清在线视频| 女性生殖器流出的白浆| 亚洲中文日韩欧美视频| 精品久久久久久久毛片微露脸| 国产激情欧美一区二区| 国产三级黄色录像| 亚洲 欧美一区二区三区| 在线免费观看的www视频| 少妇的丰满在线观看| 人人妻人人澡欧美一区二区| 99久久精品国产亚洲精品| 伊人久久大香线蕉亚洲五| 国产真实乱freesex| 亚洲中文字幕一区二区三区有码在线看 | 久久热在线av| 国产亚洲精品第一综合不卡| 一边摸一边抽搐一进一小说| 免费一级毛片在线播放高清视频| 巨乳人妻的诱惑在线观看| 好男人在线观看高清免费视频 | 成在线人永久免费视频| 一进一出抽搐动态| 婷婷精品国产亚洲av| 国产一区二区在线av高清观看| 精品一区二区三区四区五区乱码| 一本综合久久免费| 欧美黑人精品巨大| 免费在线观看成人毛片| 999久久久精品免费观看国产| 免费搜索国产男女视频| 欧美日本视频| 亚洲精品美女久久av网站| 91大片在线观看| 黄色 视频免费看| 久久精品国产亚洲av高清一级| 99精品在免费线老司机午夜| 国产又色又爽无遮挡免费看| 久久性视频一级片| 国产精品亚洲美女久久久| 国产又爽黄色视频| 一级作爱视频免费观看| 在线十欧美十亚洲十日本专区| 国产成年人精品一区二区| 中出人妻视频一区二区| 悠悠久久av| 欧美成人性av电影在线观看| 国产av一区在线观看免费| 韩国精品一区二区三区| 一级片免费观看大全| 欧美性长视频在线观看| 免费搜索国产男女视频| 精品不卡国产一区二区三区| 十八禁人妻一区二区| 国产视频一区二区在线看| 18美女黄网站色大片免费观看| 少妇 在线观看| 又大又爽又粗| 欧美亚洲日本最大视频资源| 国产国语露脸激情在线看| 成人国产一区最新在线观看| 最新在线观看一区二区三区| www日本黄色视频网| 亚洲av电影不卡..在线观看| 久久99热这里只有精品18| 国产精品久久电影中文字幕| 久久精品国产清高在天天线| 夜夜躁狠狠躁天天躁| 天堂√8在线中文| 日日爽夜夜爽网站| av在线天堂中文字幕| 欧美乱色亚洲激情| 色播亚洲综合网| 黄色成人免费大全| 午夜精品在线福利| 97碰自拍视频| www国产在线视频色| 欧美在线黄色| 国产人伦9x9x在线观看| 深夜精品福利| 中文字幕高清在线视频| 免费女性裸体啪啪无遮挡网站| 欧美精品啪啪一区二区三区| 麻豆av在线久日| 亚洲国产高清在线一区二区三 | 中文字幕精品免费在线观看视频| 亚洲国产精品成人综合色| 成年版毛片免费区| 禁无遮挡网站| 男人舔女人的私密视频| 亚洲成国产人片在线观看| 99re在线观看精品视频| 精品久久久久久久久久久久久 | 法律面前人人平等表现在哪些方面| 黄色女人牲交| 啦啦啦观看免费观看视频高清| 国产精品九九99| 黑人操中国人逼视频| 午夜亚洲福利在线播放| 亚洲欧美精品综合一区二区三区| 久久午夜亚洲精品久久| 此物有八面人人有两片| 中出人妻视频一区二区| 香蕉av资源在线| 亚洲欧美日韩高清在线视频| 精品久久久久久久毛片微露脸| 亚洲专区字幕在线| 久久天躁狠狠躁夜夜2o2o| 久久精品91蜜桃| 亚洲人成电影免费在线| 无遮挡黄片免费观看| 国产激情久久老熟女| 亚洲第一青青草原| 中文字幕高清在线视频| 成人午夜高清在线视频 | 热99re8久久精品国产| av天堂在线播放| 色综合欧美亚洲国产小说| 久久精品夜夜夜夜夜久久蜜豆 | 搡老熟女国产l中国老女人| 欧美成人性av电影在线观看| 国产精品亚洲美女久久久| 黄色视频,在线免费观看| 黑人操中国人逼视频| 国产成人精品久久二区二区免费| 丁香欧美五月| 91麻豆av在线| 国产在线观看jvid| 亚洲无线在线观看| 99国产精品99久久久久| 宅男免费午夜| 老鸭窝网址在线观看| 国产成人精品久久二区二区免费| 欧美黑人欧美精品刺激| 色尼玛亚洲综合影院| 午夜视频精品福利| 亚洲熟妇熟女久久| 制服人妻中文乱码| 午夜福利一区二区在线看| 一区二区三区精品91| 亚洲电影在线观看av| 亚洲成av人片免费观看| 午夜两性在线视频| 亚洲av电影在线进入| 亚洲欧洲精品一区二区精品久久久| 久久精品国产清高在天天线| 一卡2卡三卡四卡精品乱码亚洲| 99国产极品粉嫩在线观看| 亚洲人成电影免费在线| 亚洲精品一卡2卡三卡4卡5卡| 中亚洲国语对白在线视频| 免费无遮挡裸体视频| 99久久无色码亚洲精品果冻| 成人国产综合亚洲| 免费人成视频x8x8入口观看| 国产精品亚洲美女久久久| 欧美性猛交╳xxx乱大交人| 啦啦啦韩国在线观看视频| 欧美黑人欧美精品刺激| 91大片在线观看| 两个人免费观看高清视频| 人妻久久中文字幕网| 日韩成人在线观看一区二区三区| 18美女黄网站色大片免费观看| 日韩精品中文字幕看吧| 国产v大片淫在线免费观看| 日韩欧美国产一区二区入口| 后天国语完整版免费观看| 中文亚洲av片在线观看爽| av超薄肉色丝袜交足视频| 曰老女人黄片| 啪啪无遮挡十八禁网站| 白带黄色成豆腐渣| 搡老妇女老女人老熟妇| 不卡av一区二区三区| 亚洲九九香蕉| 中文资源天堂在线| 91成年电影在线观看| 国产激情欧美一区二区| 亚洲精品美女久久久久99蜜臀| 欧美久久黑人一区二区| 国产私拍福利视频在线观看| 国产片内射在线| 少妇被粗大的猛进出69影院| 婷婷丁香在线五月| 亚洲第一av免费看| 久久久久国产一级毛片高清牌| 2021天堂中文幕一二区在线观 | 成年版毛片免费区| 人成视频在线观看免费观看| 亚洲自偷自拍图片 自拍| 亚洲五月天丁香| 天天躁夜夜躁狠狠躁躁| 亚洲国产精品久久男人天堂| videosex国产| 变态另类成人亚洲欧美熟女| 99精品久久久久人妻精品| 男女午夜视频在线观看| 久久人妻av系列| 亚洲av电影在线进入| 亚洲专区国产一区二区| 国内精品久久久久久久电影| avwww免费| 日韩欧美在线二视频| 哪里可以看免费的av片| 亚洲最大成人中文| 国产真实乱freesex| 亚洲国产看品久久| 免费一级毛片在线播放高清视频| 亚洲国产欧美一区二区综合| 午夜福利高清视频| 成年女人毛片免费观看观看9| 宅男免费午夜| 亚洲专区字幕在线| 亚洲色图 男人天堂 中文字幕| 国产成人系列免费观看| 免费在线观看日本一区| 日韩av在线大香蕉| 自线自在国产av| 欧美日韩亚洲国产一区二区在线观看| 一二三四社区在线视频社区8| 欧美乱色亚洲激情| 后天国语完整版免费观看| 啦啦啦免费观看视频1| 成人一区二区视频在线观看| 免费搜索国产男女视频| 亚洲av成人不卡在线观看播放网| 国产av一区在线观看免费| 黑丝袜美女国产一区| 日韩中文字幕欧美一区二区| 成年女人毛片免费观看观看9| 国产私拍福利视频在线观看| 在线观看舔阴道视频| 日韩高清综合在线| 午夜福利18| 怎么达到女性高潮| 亚洲黑人精品在线| 国产精品久久久久久亚洲av鲁大| 法律面前人人平等表现在哪些方面| 午夜福利免费观看在线| 中文亚洲av片在线观看爽| 欧美中文日本在线观看视频| 国产欧美日韩精品亚洲av| 欧美不卡视频在线免费观看 | 亚洲欧洲精品一区二区精品久久久| 欧美激情极品国产一区二区三区| 亚洲欧美精品综合一区二区三区| 99久久精品国产亚洲精品| 色综合亚洲欧美另类图片| 国产亚洲精品一区二区www| 国产色视频综合| 中文字幕人成人乱码亚洲影| 久久国产亚洲av麻豆专区| 这个男人来自地球电影免费观看| 波多野结衣高清无吗| 日韩欧美国产在线观看| 性色av乱码一区二区三区2| 国产午夜福利久久久久久| 成人亚洲精品av一区二区| 亚洲无线在线观看| 亚洲五月色婷婷综合| 欧美中文日本在线观看视频| 啦啦啦 在线观看视频| 国产精品98久久久久久宅男小说| 日韩一卡2卡3卡4卡2021年| 欧美激情 高清一区二区三区| 中文字幕精品免费在线观看视频| 精品熟女少妇八av免费久了| 国产av一区二区精品久久| 成人永久免费在线观看视频| tocl精华| 一区二区日韩欧美中文字幕| 香蕉久久夜色| 久久久国产成人免费| 少妇被粗大的猛进出69影院| 无限看片的www在线观看| 久99久视频精品免费| 国产一卡二卡三卡精品| www日本在线高清视频| 99热6这里只有精品| 欧美黑人欧美精品刺激| 久久久久国产精品人妻aⅴ院| 18禁黄网站禁片午夜丰满| 精品乱码久久久久久99久播| 色老头精品视频在线观看| 欧美色欧美亚洲另类二区| 亚洲国产欧洲综合997久久, | 午夜精品在线福利| 一区二区日韩欧美中文字幕| 精品国产国语对白av| 99在线视频只有这里精品首页| 日韩欧美一区二区三区在线观看|